Composition, form of production and packaging
? Capsules hard gelatinous, white; the content of the capsules is a fine crystalline hygroscopic powder white or white with a yellowish hue.
1 caps.
interferon alpha-2b human recombinant 500,000 IU
[PRING] sodium chloride - 8.01 mg, sodium phosphate, disubstituted, 12-aqueous (sodium hydrophosphate dodecahydrate) 4.52 mg, sodium dihydrogen phosphate sodium dihydrate phosphate monosubstituted 2-water 0.56 mg, lactose monohydrate 91.34 mg, silicon dioxide colloidal anhydrous - 7.54 mg (not more than 5%).
The composition of the capsule shell (body and cover): titanium dioxide (E171) - 2%, gelatin - up to 100%.
10 pieces. - bottles of high-density polyethylene (1) - packs of cardboard.
20 pcs. - bottles of high-density polyethylene (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2015.
PHARMACHOLOGIC EFFECT
The drug has an immunomodulatory and antiviral effect. Interferon alfa-2b human recombinant, which is an active substance in the preparation, is synthesized by bacterial cells of the strain of Escherichia coli SG-20050 / plF16, the human interferon alpha-2b gene is embedded in the genetic apparatus. It is a protein containing 165 amino acids, and is identical in characteristics and properties to human leukocyte interferon alpha-2b.
The antiviral effect of interferon alfa-2b is manifested during the reproduction of the virus by active incorporation into the metabolic processes of the cells. Interferon, interacting with specific receptors on the surface of cells, initiates a number of intracellular changes, including the synthesis of specific cytokines and enzymes (2-5-adenylate synthetase and protein kinase), the action of which inhibits the formation of viral protein and viral ribonucleic acid in the cell .
The immunomodulatory effect of interferon alfa-2b is manifested in an increase in phagocytic activity of macrophages, enhancement of the specific cytotoxic effect of lymphocytes on target cells, changes in the quantitative and qualitative composition of secreted cytokines; changes in the functional activity of immunocompetent cells; changes in the production and secretion of intracellular proteins.
INDICATIONS
- treatment of influenza and other acute respiratory viral diseases in adults as part of complex therapy;
- prevention of influenza and other acute respiratory viral diseases in adults during epidemics and seasonal morbidity.
DOSING MODE
The drug is taken orally, 30 minutes before meals.
When treating influenza and ARVI - 500 000 ME (1 capsule) daily 2 times / day for 5 days.
For the prevention of influenza and ARVI - 500 000 ME (1 capsule) per day, 2 times a week for a month.
If swallowing is difficult, capsules are carefully opened and the contents taken with a small amount of water.
SIDE EFFECT
Allergic reactions are possible, flu-like syndrome (chills, fever, fatigue, lethargy, headache, myalgia, arthralgia, decreased appetite).
CONTRAINDICATIONS
- children's age till 18 years;
- Pregnancy;
- lactation period;
- lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome;
- Hypersensitivity to interferon or any other components of the drug.
Carefully
renal and / or hepatic insufficiency;
- expressed myelosuppression.
PREGNANCY AND LACTATION
The drug is contraindicated for use in pregnancy and lactation.
SPECIAL INSTRUCTIONS
In case of allergic reactions, it is necessary to consult a doctor.
Influence on ability to drive vehicles, mechanisms
The use of the drug does not affect the ability to drive a vehicle or potentially dangerous mechanisms.
OVERDOSE
There were no cases of drug overdose. It is possible to increase dose-dependent side effects. Treatment is symptomatic.
DRUG INTERACTION
Interferon alfa is able to reduce the activity of P450 cytochromes and, consequently, affect the metabolism of cimetidine, fepitoip, curantyl, theophylline, diazepam, propranolol, warfarin. some cytostatics. May enhance neurotoxic. myelotoxic or cardiotoxic effect of drugs administered earlier or simultaneously with it. Joint use with drugs, depressing CNS, immunosuppressive drugs (including oral and parenteral forms of corticosteroids) should be avoided. Drinking alcohol during treatment is not recommended.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored in a place protected from light and inaccessible to children at a temperature of no higher than 8 В° C. Shelf life - 2 years.
Not applicable after the expiration date printed on the package.
